INT242211

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.36
First Reported 2008
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 9
Total Number 9
Disease Relevance 3.40
Pain Relevance 0.26

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

small molecule metabolic process (GLP1R) plasma membrane (GLP1R) signal transducer activity (GLP1R)
Anatomy Link Frequency
blood 1
plasma 1
GLP1R (Homo sapiens)
Pain Link Frequency Relevance Heat
agonist 28 99.48 Very High Very High Very High
Neuropeptide 12 52.40 Quite High
Central nervous system 4 51.20 Quite High
potassium channel 6 7.12 Low Low
adenocard 10 5.00 Very Low Very Low Very Low
headache 10 5.00 Very Low Very Low Very Low
tolerance 9 5.00 Very Low Very Low Very Low
Inflammation 7 5.00 Very Low Very Low Very Low
abdominal pain 6 5.00 Very Low Very Low Very Low
chemokine 6 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Diabetes Mellitus 518 100.00 Very High Very High Very High
Hyperglycemia 41 83.48 Quite High
Cardiovascular Disease 59 82.16 Quite High
Hypoglycemia 91 79.20 Quite High
Weight Gain 44 68.88 Quite High
Disease 56 66.24 Quite High
Hyperinsulinism 11 61.76 Quite High
Apoptosis 3 46.56 Quite Low
Body Weight 43 39.44 Quite Low
Congenital Anomalies 10 34.40 Quite Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Conversely, hyperglycaemia acutely reduces the postprandial levels of GIP and GLP-1, possibly through a deceleration of gastric emptying.
Negative_regulation (reduces) of GLP-1
1) Confidence 0.36 Published 2010 Journal Pediatr Nephrol Section Body Doc Link PMC2874027 Disease Relevance 0.51 Pain Relevance 0.05
Role of saxagliptin as monotherapy or adjunct therapy in the treatment of type 2 diabetes

Type 2 diabetes is associated with decreased incretin hormone response to an oral glucose load, and a progressive decline in postprandial glucagon-like peptide-1 (GLP-1) secretion.

Negative_regulation (decline) of glucagon-like peptide-1 associated with diabetes mellitus
2) Confidence 0.33 Published 2010 Journal Therapeutics and Clinical Risk Management Section Title Doc Link PMC2878957 Disease Relevance 0.29 Pain Relevance 0
Patients with type 2 diabetes exhibit an attenuated insulinotropic action of GIP but not GLP-1 and a significant reduction in meal-stimulated levels of GLP-1 (Nauck et al 1993; Toft-Nielsen et al 2001).
Negative_regulation (reduction) of GLP-1 associated with diabetes mellitus
3) Confidence 0.27 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2597770 Disease Relevance 0.32 Pain Relevance 0.04
The strategy of inhibiting DPP-4 is to prevent the inactivation of GLP-1 and therefore to enhance and prolong the effects of the endogenously released incretin hormone.
Negative_regulation (inactivation) of GLP-1
4) Confidence 0.27 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2597770 Disease Relevance 0.22 Pain Relevance 0
Patients with type 2 diabetes exhibit an attenuated insulinotropic action of GIP but not GLP-1 and a significant reduction in meal-stimulated levels of GLP-1 (Nauck et al 1993; Toft-Nielsen et al 2001).
Negative_regulation (reduction) of GLP-1 associated with diabetes mellitus
5) Confidence 0.27 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2597770 Disease Relevance 0.32 Pain Relevance 0.07
GLP-1 levels after DPP-4 inhibition are increased, resulting in stimulation of insulin secretion and suppression of glucagon secretion in a fashion which is glucose-dependent (ie, glucose-appropriate).
Negative_regulation (inhibition) of GLP-1
6) Confidence 0.16 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2597758 Disease Relevance 0.12 Pain Relevance 0
Sitagliptin, the first commercially available dipeptidyl peptidase-4 inhibitor, inhibits the metabolism and inactivation of the incretin hormones GLP-1 and GIP.
Negative_regulation (inactivation) of GLP-1
7) Confidence 0.16 Published 2008 Journal Vascular Health and Risk Management Section Abstract Doc Link PMC2597758 Disease Relevance 0.58 Pain Relevance 0
Individuals with type 2 diabetes are GLP-1 deficient; however, infusion of GLP-1 to persons with diabetes has been shown to lower both postprandial and fasting blood glucose levels (Drucker 2003; Aronoff et al 2004).
Negative_regulation (deficient) of GLP-1 in blood associated with diabetes mellitus
8) Confidence 0.16 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2597758 Disease Relevance 0.41 Pain Relevance 0
GLP-1 secretion may be impaired in T2DM, and GLP-1 analogs and agonists and DPP-4 inhibitors that increase endogenous GLP-1 production have the advantage that their effect on insulin secretion depends on plasma glucose concentration.
Negative_regulation (impaired) of GLP-1 in plasma associated with diabetes mellitus and agonist
9) Confidence 0.03 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2515417 Disease Relevance 0.65 Pain Relevance 0.10

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox